Answers are grounded in this paper and cite their sources.
Explores APOL1 risk variants and their impact on cytotoxicity in podocytes, suggesting new treatment avenues.
BACKGROUND: The mechanisms by which apolipoprotein L1 (APOL1) risk variants, G1 and G2, induce kidney disease in individuals of African ancestry remain contentious. METHODS: In this study, we utilized a heterologous expression system of HEK-293 cells and human podocytes to investigate APOL1-mediated cytotoxicity using genetic, electrophysiological, and microscopy-based approaches. RESULTS: APOL1 variants showed dynamic transport in vesicle-like structures towards the plasma membrane via actin filaments. At the plasma membrane, the non-risk APOL1 G0 and risk variants formed non-selective cation-permeable pores for Na+ and Ca2+, exhibiting functional activity under basal conditions. Extracellular Ca2+ was identified as the primary source of Ca2+ influx through APOL1, leading to cytotoxicity. APOL1 risk variants exhibited increased basal channel activity compared to non-risk APOL1 G0, resulting in haplotype-dependent cytotoxicity. Furthermore, we observed that both the M1 (N264K) variant and APOL1 inhibitor, VX-147, exerted protective effects on cell viability by blocking the APOL1-dependent intracellular Ca2+ influx. CONCLUSIONS: This study demonstrated APOL1 to be a membrane protein involved in the influx of Ca2+ from the extracellular medium. Increased activity of APOL1 led to markedly increased cytotoxicity, which supports the gain-of-function theory. This effect was prevented by the presence of N264K variant or treatment with the APOL1 inhibitor VX-147.
No takes yet. Share an insight, caveat, or question.
Adebayo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: